Literature DB >> 10561303

Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.

J A Ajani1, P F Mansfield, P M Lynch, P W Pisters, B Feig, P Dumas, D B Evans, I Raijman, K Hargraves, S Curley, D M Ota.   

Abstract

PURPOSE: Patients with local-regional gastric carcinoma have a low rate of curative resection (R0) because of the advanced stage at diagnosis and suboptimal clinical staging. This study was designed to improve clinical staging with the use of laparoscopy and endoscopic ultrasonography (EUS) and to improve R0 resection rates and tolerance by delivering all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. PATIENTS AND METHODS: All patients with histologic proof of localized adenocarcinoma of the stomach underwent a staging laparoscopy before registration. EUS was performed when feasible. The intention was to administer up to five courses of preoperative chemotherapy consisting of fluorouracil (500 mg/m(2)/d as a continuous infusion on days 1 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three times a week for 3 weeks), and cisplatin (15 mg/m(2)/d as a bolus on days 1 through 5). After chemotherapy, surgery was attempted to remove the primary and regional lymph nodes. Clinical response and EUS staging were correlated with surgical pathology. The feasibility of this approach, resection rates, patient survival, and patterns of failure also were assessed.
RESULTS: All 30 patients enrolled were assessed for toxicity, response, and survival. Nineteen men and 11 women were enrolled. The median number of courses delivered per patient was three (range, one to five courses). Fourteen patients (47%) received all five preoperative courses of chemotherapy. The overall clinical response rate was 34%. Twenty-nine patients (97%) underwent attempted resection. Twenty-five (83%) had an R0 resection. Two patients (7%) had no evidence of carcinoma in the surgical specimen, and three had only microscopic carcinoma (>/= 90% necrosis). Posttreatment EUS findings did not correlate well with surgical pathology. The median duration of follow-up was 30 months (range, 5 months to 65+ months). The median survival time for 30 patients, calculated by the Kaplan-Meier method, was 30 months (range, 5 months to 65+ months). There were no cases of grade 4 toxicity.
CONCLUSION: It is feasible to administer prolonged preoperative therapy in patients with potentially resectable gastric carcinoma. Enhanced staging with laparoscopy and EUS helped in proper selection of patients and better characterization of the stage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561303     DOI: 10.1200/JCO.1999.17.8.2403

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

Review 1.  Neoadjuvant therapy for gastric cancer: current evidence and future directions.

Authors:  Andrew D Newton; Jashodeep Datta; Arturo Loaiza-Bonilla; Giorgos C Karakousis; Robert E Roses
Journal:  J Gastrointest Oncol       Date:  2015-10

2.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

3.  Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer.

Authors:  Kentaro Inoue; Yasushi Nakane; Taku Michiura; Sou Yamaki; Rintaro Yui; Kazuhito Sakuramoto; Aiko Iwai; Katsuji Tokuhara; Yoshiro Araki; Songtae Kim; Koji Nakai; Mutsuya Sato; Keigo Yamamichi; A-Hon Kwon
Journal:  Surg Endosc       Date:  2009-01-30       Impact factor: 4.584

Review 4.  Monitoring chemotherapy and radiotherapy of solid tumors.

Authors:  Wolfgang A Weber; Hinrich Wieder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

Review 5.  Treatment options for surgically resectable gastric cancer.

Authors:  Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2010-06

6.  A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.

Authors:  Young-Woo Kim; Mi-Jung Kim; Keun Won Ryu; Hyeong-Seok Lim; Jun Ho Lee; Sun-Young Kong; Jong Seok Lee; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo-Jeong Cho; Myeong-Cherl Kook; Young-Iee Park; Seok-Ki Kim; Sook Ryun Park
Journal:  Gastric Cancer       Date:  2015-04-08       Impact factor: 7.370

7.  Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials.

Authors:  Jian-Kun Hu; Zhi-Xin Chen; Zong-Guang Zhou; Bo Zhang; Jing Tian; Jia-Ping Chen; Li Wang; Chao-Hua Wang; Hong-Yan Chen; You-Ping Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

8.  Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.

Authors:  Elliot Newman; Stuart G Marcus; Milan Potmesil; Sanjeev Sewak; Herman Yee; Joan Sorich; Mary Hayek; Franco Muggia; Howard Hochster
Journal:  J Gastrointest Surg       Date:  2002 Mar-Apr       Impact factor: 3.452

9.  Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.

Authors:  F Bataille; P Rümmele; W Dietmaier; D Gaag; F Klebl; A Reichle; P Wild; F Hofstädter; A Hartmann
Journal:  Mol Pathol       Date:  2003-10

10.  Adjuvant and preoperative therapy for localized gastric cancer.

Authors:  Yixing Jiang; Alberto J Montero; Kevin F Staveley-O'Carroll
Journal:  Gastrointest Cancer Res       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.